Health Care & Life Sciences » Pharmaceuticals | KPC Pharmaceuticals Inc.

KPC Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values CNY Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
3,561
4,288
4,879
5,055
5,790
7,020
Cost of Goods Sold (COGS) incl. D&A
2,551
3,030
3,245
3,153
3,265
3,617
Gross Income
1,010
1,258
1,634
1,901
2,525
3,403
SG&A Expense
716
912
1,152
1,488
2,149
3,024
EBIT
286
-
470
454
373
375
Unusual Expense
-
3
-
-
2
3
Non Operating Income/Expense
1
5
5
5
42
41
Interest Expense
27
24
24
26
28
46
Pretax Income
284
370
507
488
422
423
Income Tax
48
62
75
71
73
75
Equity in Affiliates
-
-
1
7
14
6
Consolidated Net Income
236
308
431
410
335
342
Net Income
232
289
421
407
330
336
Net Income After Extraordinaries
232
289
421
407
330
336
Net Income Available to Common
232
289
421
407
330
336
EPS (Basic)
0.36
0.42
0.53
0.52
0.42
0.44
Basic Shares Outstanding
651
682
789
789
786
769
EPS (Diluted)
0.36
0.42
0.53
0.52
0.42
0.44
Diluted Shares Outstanding
651
682
789
789
786
769
EBITDA
332
401
550
532
471
484
Other Operating Expense
8
17
13
40
3
3
Non-Operating Interest Income
10
28
21
50
37
57
Minority Interest Expense
4
19
10
2
5
6

About KPC Pharmaceuticals

View Profile
Address
No. 166 Keyi Road
Kunming Yunnan 650106
China
Employees -
Website http://www.kpc.com.cn
Updated 07/08/2019
KPC Pharmaceuticals, Inc. engages in the research and development, manufacture, sale, commercial wholesale, and international marketing of drugs. It focuses on natural herbal-based Chinese medicine, chemical medicine, and pharmaceutical area. Its products include panax notoginseng, gastrodine, artemether, and special botanical drugs.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.